|
|
Upfront Briefing
Travere got an FDA green light for Filspari in FSGS — a clean way to expand the commercial lane for a kidney franchise investors already model.
Same agency, different vibe: FDA asked for more safety data on Lilly’s Foundayo (heart, liver and gastric-emptying risk), while Spyre tapped markets with an upsized $403M offering (cash now, dilution later).
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
6,967.4 |
+1.2% |
+0.6% |
| Nasdaq 100 |
25,842.0 |
+1.8% |
+1.5% |
| Russell 2000 |
2,705.7 |
+1.3% |
+2.0% |
| Healthcare (XLV) |
148.8 |
+0.6% |
(5.3%) |
| Biotech (XBI) |
135.7 |
+2.8% |
+7.0% |
| Nasdaq Biotech (NBI) |
6,067.1 |
+2.0% |
+3.9% |
| Clinical Trials (BBC) |
45.4 |
+2.1% |
+9.4% |
|
- Risk-on tone strengthened as hopes for renewed U.S.-Iran talks and easing oil prices pulled investors back into growth, pushing the S&P 500 up 1.2% and the Nasdaq complex sharply higher.
- Biotech outperformed defensives: XBI (+2.8%), NBI (+2.0%) and BBC (+2.1%) all beat XLV (+0.6%), suggesting investors moved beyond a simple defensive-healthcare bid and further out the duration / development-risk curve.
- Small caps also participated, with the Russell 2000 up 1.3%, reinforcing that Tuesday's rally was a genuine risk-on rebound rather than a narrow megacap squeeze.
- Market data: U.S. close Tue 14-Apr-2026.
The Big 3
|
1
|
Travere wins FDA approval for Filspari in FSGS
|
- Travere won FDA approval for Filspari in FSGS. The clearance supports a broader commercial opportunity and updates expectations for the franchise’s durability.
- Why it matters: This is a true label-expansion revenue event, not just a regulatory headline. FILSPARI was already commercial in IgAN; adding first-to-market FSGS broadens the U.S. addressable pool to more than 100,000 patients, adds a second renal-growth leg and gives investors a cleaner setup for peak-sales, operating-leverage and franchise-durability assumptions.
- Source: BioPharma Dive
- More: Fierce Pharma
|
|
2
|
Spyre prices upsized $403M public offering
|
- Spyre Therapeutics priced an upsized $403.0 million public offering at $62 per share. The financing materially extends runway as the company advances its anti-TL1A programs, but it also brings immediate dilution after a sharp post-data rerating.
- Why it matters: After SPY001's ulcerative colitis data reopened upside around best-in-class TL1A potential, management used the window to pull forward capital. For investors, the key debate now shifts from financing risk to dilution, ownership reset and whether the enlarged cash balance is enough to fund the next value-inflection data without another near-term raise.
-
Source:
PR
|
| 3 | FDA asks for more safety data on Lilly’s Foundayo |
-
FDA is seeking additional data on Lilly’s Foundayo to assess heart, liver and gastric-emptying risks. Added scrutiny could shape labeling and monitoring expectations.
- Why it matters: The key point for investors is that this appears to be a post-marketing evidence burden rather than a pre-launch approval setback. Still, added cardiovascular, hepatic and gastric-emptying work could shape the eventual label, monitoring intensity and payer / prescriber comfort, which matters in a category where convenience alone may not be enough to win share.
-
Source:
Endpoints
|
Everything Else that broke
- Astellas is shutting its Seattle-area stem cell unit and cutting jobs, another reminder that platform resets and portfolio pruning are still part of the 2026 biotech operating backdrop. — Fierce Biotech
- FDA issued draft safety guidance for bespoke gene therapies, a regulatory update worth watching for rare-disease and individualized-CGT developers. — BioSpace
- Partner Therapeutics submitted an sBLA for BIZENGRI in NRG1+ cholangiocarcinoma, extending the commercial expansion story around a niche precision-oncology asset. — PR
- Next-gen TYK2 inhibitors stayed in focus after fresh Phase 3 psoriasis data, a useful readthrough for the broader oral immunology competitive set. — BioCentury
- NMPA cleared SynuSight / Mabwell's α-syn PET tracer to enter the clinic, an early but notable marker for neurodegeneration imaging competition. — PR
- Zentalis led movers in a trio of ovarian-cancer updates, keeping DNA-damage-response names active on the oncology tape. — BioCentury
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
ICYMI: Regeneron and Telix struck a radiopharma collaboration worth $40M upfront plus up to $2.1B in milestones, with a 50/50 co-development and profit-share option across four initial solid-tumor programs. — Company PR
-
Lilly agreed to acquire CrossBridge Bio for up to $300M, adding a preclinical dual-payload ADC platform and another oncology bolt-on to its active M&A run. — Fierce Biotech
VC / Private Financings
- Neomorph closed a $100M Series B led by Deerfield Management, joined by Regeneron Ventures, Longwood Fund, Alexandria Venture Investments and Binney Street Capital, to back its molecular-glue degrader pipeline. — Fierce fundraising tracker
- Spiral Therapeutics closed a $27M Series B led by Gund Investment, joined by Advanced Bionics, Ferring Ventures and Uni-Bio Science Group alongside existing backers. — PR
IPOs / Follow-Ons
- Telix priced and upsized US$600M of convertible bonds. — PR
- Spyre Therapeutics priced an upsized $403.0M follow-on at $62 per share after initially filing for $300M. — PR
- Kailera and Alamar are both in market with U.S. IPO launches, with Kailera marketing 33.3M shares at $14-$16 and Alamar 9.4M shares at $15-$17, keeping the biotech new-issue window active beyond follow-ons and giving investors a cleaner read on real demand rather than just pipeline chatter. — Reuters
- Obsidian is taking the reverse-merger route via Galera, another reminder that public-market access is reopening through multiple structures, not just traditional IPOs. — Fierce Biotech
Things that make you go hmmm ...
IPO pipeline heating up ... Source: Guggenheim
Academic Corner - Fast and accurate multiple-protein-sequence alignment at scale with FAMSA2. — Nature Biotech
- KRAS-targeting PROTAC drug passes first clinical test. — Nature Medicine
- Intravitreal photoswitch therapy in advanced retinitis pigmentosa: a phase 1 open-label trial. — Nature Medicine
- Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial. — Nature Medicine
|
|
That’s it for today — congrats to Travere, condolences to everyone updating an obesity safety slide. See you tomorrow. BioBucks Team
|
|
|
